Further Information
SUMO2/3 Antibody: HSMT3, SMT3B, SUMO3, Smt3A, SMT3H2, SMT3A, Small ubiquitin-related modifier 2, HSMT3, SUMO-2
Immunofluorescence: 0.5-1 ug/ml
Immunohistochemistry (FFPE): 0.5-1 ug/ml for 30 min at RT (1)
Prediluted format: incubate for 30 min at RT (2)
Titering of the SUMO-2 antibody may be required for optimal performance.
1. FFPE testing requires sections to be boiled in pH6 10mM citrate buffer for 10-20 minutes, followed by cooling at RT for 20 minutes, prior to staining.
2. The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required), drip mAb solution onto the tissue section and incubate at RT for 30 min.
The small ubiquitin-related modifier (SUMO) proteins, which include SUMO-1, 2 and 3, belong to the ubiquitin-like protein family. Like ubiquitin, the SUMO proteins are synthesized as precursor proteins that undergo processing before conjugation to target proteins. Sumoylation targets proteins to a variety of cellular processing, including nuclear transport, transcriptional regulation, apoptosis and protein stability. The unconjugated SUMO-1, 2 and 3 proteins localize to the nuclear membrane, nuclear bodies and cytoplasm, respectively. SUMO-2 and 3 contribute to a greater percentage of protein modification than does SUMO-1 and unlike SUMO-1, they can form polymeric chains.
PBS with 0.1 mg/ml BSA and 0.05% sodium azide
0.2 mg/mL
Unconjugated
Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
Recombinant human protein was used as the immunogen for the SUMO-2 antibody.
6613
SMT3 suppressor of mif two 3 homolog 2 (S. cerevisiae)
SUMO2
Homo sapiens
Liquid
Protein G affinity chromatography
Homeostasis
P61956
Optimal dilutions for each application to be determined by the researcher
